Tiago Fauth
Stock Analyst at Wells Fargo
(0.98)
# 3,163
Out of 4,667 analysts
123
Total ratings
26.83%
Success rate
-19.09%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Tiago Fauth
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TECX Tectonic Therapeutic | Maintains: Overweight | $55 → $79 | $44.03 | +79.42% | 2 | Nov 12, 2024 | |
| VRNA Verona Pharma | Maintains: Overweight | $50 → $64 | $38.85 | +64.74% | 2 | Nov 5, 2024 | |
| WVE Wave Life Sciences | Maintains: Overweight | $11 → $22 | $14.26 | +54.28% | 2 | Oct 16, 2024 | |
| IRON Disc Medicine | Initiates: Overweight | $75 | $62.55 | +19.90% | 1 | Aug 22, 2024 | |
| UTHR United Therapeutics | Maintains: Overweight | $350 → $380 | $364.33 | +4.30% | 4 | Aug 20, 2024 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Overweight | $72 → $75 | $46.40 | +61.64% | 6 | Aug 2, 2024 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Equal-Weight | $207 → $233 | $248.79 | -6.35% | 4 | Aug 2, 2024 | |
| AVTE Aerovate Therapeutics | Downgrades: Equal-Weight | $35 → $2 | $2.66 | -24.81% | 2 | Jun 18, 2024 | |
| INZY Inozyme Pharma | Initiates: Overweight | $14 | $2.79 | +401.79% | 1 | May 30, 2024 | |
| INSM Insmed | Maintains: Overweight | $55 → $77 | $72.67 | +5.96% | 2 | May 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $60 | $54.14 | +10.82% | 1 | Dec 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $63 → $62 | $1.72 | +3,504.65% | 5 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Neutral | $89 | $124.38 | -28.45% | 16 | Jun 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $51 | $19.79 | +157.71% | 3 | Jun 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $120 | $62.56 | +91.82% | 7 | Jun 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $120 | $3.15 | +3,709.52% | 6 | May 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Underperform | $4 | $26.17 | -84.72% | 4 | May 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $14 | $2.68 | +422.39% | 4 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $4 | $0.49 | +716.33% | 5 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $26 | $15.91 | +63.42% | 5 | May 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $28 | $2.67 | +948.69% | 7 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $70 → $81 | $27.49 | +194.65% | 11 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $8 | $1.48 | +440.54% | 5 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $14 | $3.82 | +266.49% | 2 | Mar 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $38 → $34 | $1.21 | +2,709.92% | 2 | Mar 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $150 | $5.81 | +2,481.76% | 2 | Mar 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $29 | $34.65 | -16.31% | 1 | Jan 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $13 | $3.90 | +233.33% | 1 | Dec 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $25 → $13 | $2.41 | +439.42% | 2 | Nov 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $2.5 → $2 | $2.04 | -1.96% | 4 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $297 → $340 | $591.82 | -42.55% | 3 | Dec 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $265 → $259 | $287.87 | -10.03% | 1 | Apr 28, 2021 |
Tectonic Therapeutic
Nov 12, 2024
Maintains: Overweight
Price Target: $55 → $79
Current: $44.03
Upside: +79.42%
Verona Pharma
Nov 5, 2024
Maintains: Overweight
Price Target: $50 → $64
Current: $38.85
Upside: +64.74%
Wave Life Sciences
Oct 16, 2024
Maintains: Overweight
Price Target: $11 → $22
Current: $14.26
Upside: +54.28%
Disc Medicine
Aug 22, 2024
Initiates: Overweight
Price Target: $75
Current: $62.55
Upside: +19.90%
United Therapeutics
Aug 20, 2024
Maintains: Overweight
Price Target: $350 → $380
Current: $364.33
Upside: +4.30%
Ultragenyx Pharmaceutical
Aug 2, 2024
Maintains: Overweight
Price Target: $72 → $75
Current: $46.40
Upside: +61.64%
Alnylam Pharmaceuticals
Aug 2, 2024
Maintains: Equal-Weight
Price Target: $207 → $233
Current: $248.79
Upside: -6.35%
Aerovate Therapeutics
Jun 18, 2024
Downgrades: Equal-Weight
Price Target: $35 → $2
Current: $2.66
Upside: -24.81%
Inozyme Pharma
May 30, 2024
Initiates: Overweight
Price Target: $14
Current: $2.79
Upside: +401.79%
Insmed
May 29, 2024
Maintains: Overweight
Price Target: $55 → $77
Current: $72.67
Upside: +5.96%
Dec 8, 2023
Initiates: Overweight
Price Target: $60
Current: $54.14
Upside: +10.82%
Aug 11, 2023
Maintains: Outperform
Price Target: $63 → $62
Current: $1.72
Upside: +3,504.65%
Jun 14, 2023
Assumes: Neutral
Price Target: $89
Current: $124.38
Upside: -28.45%
Jun 14, 2023
Assumes: Outperform
Price Target: $51
Current: $19.79
Upside: +157.71%
Jun 14, 2023
Assumes: Outperform
Price Target: $120
Current: $62.56
Upside: +91.82%
May 26, 2023
Reiterates: Outperform
Price Target: $120
Current: $3.15
Upside: +3,709.52%
May 23, 2023
Reiterates: Underperform
Price Target: $4
Current: $26.17
Upside: -84.72%
May 16, 2023
Reiterates: Outperform
Price Target: $14
Current: $2.68
Upside: +422.39%
May 16, 2023
Reiterates: Outperform
Price Target: $4
Current: $0.49
Upside: +716.33%
May 11, 2023
Reiterates: Outperform
Price Target: $26
Current: $15.91
Upside: +63.42%
May 5, 2023
Maintains: Outperform
Price Target: $34 → $28
Current: $2.67
Upside: +948.69%
May 5, 2023
Maintains: Neutral
Price Target: $70 → $81
Current: $27.49
Upside: +194.65%
Mar 24, 2023
Reiterates: Neutral
Price Target: $8
Current: $1.48
Upside: +440.54%
Mar 23, 2023
Reiterates: Outperform
Price Target: $14
Current: $3.82
Upside: +266.49%
Mar 10, 2023
Maintains: Outperform
Price Target: $38 → $34
Current: $1.21
Upside: +2,709.92%
Mar 10, 2023
Reiterates: Outperform
Price Target: $150
Current: $5.81
Upside: +2,481.76%
Jan 26, 2023
Initiates: Outperform
Price Target: $29
Current: $34.65
Upside: -16.31%
Dec 16, 2022
Initiates: Outperform
Price Target: $13
Current: $3.90
Upside: +233.33%
Nov 18, 2022
Downgrades: Neutral
Price Target: $25 → $13
Current: $2.41
Upside: +439.42%
May 13, 2022
Maintains: Underperform
Price Target: $2.5 → $2
Current: $2.04
Upside: -1.96%
Dec 20, 2021
Maintains: Neutral
Price Target: $297 → $340
Current: $591.82
Upside: -42.55%
Apr 28, 2021
Maintains: Outperform
Price Target: $265 → $259
Current: $287.87
Upside: -10.03%